6 analysts have shared their evaluations of Metagenomi (NASDAQ:MGX) during the recent three months, expressing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have recently evaluated Metagenomi and provided 12-month price targets. The average target is $11.83, accompanied by a high estimate of $17.00 and a low estimate of $7.00. Highlighting a 12.37% decrease, the current average has fallen from the previous average price target of $13.50.

Decoding Analyst Ratings: A Detailed Look

The standing of Metagenomi among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Metagenomi's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Metagenomi analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Metagenomi

Unraveling the Financial Story of Metagenomi

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Metagenomi's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 76.48%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Metagenomi's net margin excels beyond industry benchmarks, reaching -53.67%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Metagenomi's ROE excels beyond industry benchmarks, reaching -3.94%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Metagenomi's ROA excels beyond industry benchmarks, reaching -2.68%. This signifies efficient management of assets and strong financial health.

Debt Management: Metagenomi's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.